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Between 1977 and 1978, 239 patients underwent aortic valve replacement with either a bioprosthesis (100,
BIO) or a Bjork-Shiley tilting disc prosthesis (139, BS). Early mortality was 2%, late mortality 4%. There
was no statistically significant difference between the two groups. Anticoagulation was maintained
indefinitively in patients with a BS, after implantation of a BIO only for three months except in the presence
of atrial fibrillation or a history ofeinboli. ThromboeinboUc complications and anticoagulant hemorrhages
were almost twice as frequent in patients with BS than with BIO (5'3 versus 2m8 episodes/100 patient years).
This difference however is statistically not significant. There were an equal number (two) of reoperations
because ofparavalvular leaks due to endocarditis or torn sutures in the two groups. A regurgitant murmur,
though hemodynamically not significant, occurred more frequently in patients with BIO than with BS
(10% versus 2%, P < 005). Its cause and importance cannot yet be determined. Postoperative results
judged by the NYHA classification and reduction of heart size were similar in both groups. Of all patients,
13% with preoperative valvular incompetence and 15% with stenosis showed little or no reduction of the
cardiothoracic ratio on X-ray indicating a worse long-term prognosis. The porcine BIO has become our
preferred valvular substitute because of its low thromboembolic complication rate. The BS is mainly
reserved for patients already on anticoagulants for other reasons.
From 1971 to 1977 the Bjork-Shiley prosthesis (BS) during this time period, the BS being the preferred
has been our preferred valvular substitute for aortic choice during the early part of this series, whereas
valve replacement (AVR). We have since started to later the BIO was used more often. The pre-
use porcine bioprostheses (BIO) in increasing operative and operative data are outlined in Table
numbers because of their lower reported incidence 1. On statistical analysis (Student's'/-test, chi-
of thromboembolic complications as compared to square test) patients receiving a BIO were generally
mechanical devices!'-1]. This retrospective study younger with less advanced disease. Operative
analyses first results with BIO in reference to valve technique was the same in both groups (moderate
related complications and compares them to those hypothermia to 26-28°C, K+ induced cardioplegia
achieved with the BS over the same time period. and topical hypothermia). Postoperatively all
patients with a BS received long-term anticoagu-
Patients and methods
 l a n t s P a t i e m s w i t h a B I 0 w e r e a n t i c o a g u i a t e d f o r
During 1977 and 1978, 239 patients underwent three months; in these patients anticoagulation was
isolated AVR with either a BIO or a BS. BIO of continued only iiTthe presence of atrial fibrillation
three different manufacturers were used: Carpentier or a history of preoperative emboli. The follow-up
Edwards (51), Angell-Shiley (41) and Hancock (8). period lasted to June 1979 with a mean of 13
Indications for implanting a BIO or BS varied months for the BIO patients and 20 months for
patients with a BS. To evaluate reduction in heart
size postoperatively the cardiothoracic ratio (CTR)
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 i n p r e_ a n d s i x months postoperative chest X-rays
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University Hospital, Zurich. Switzerland. upright position were considered for comparison.
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Table 1 Preoperative and operative data
Number of patients
Male/female ratio
Mean age (years)
Predominant stenosis
Predominant regurgitation
Mixed lesion
NYHA class (mean)
ci. (mean)
Concomitant procedures
CABG
Patch enlargement of aortic root
Resection of asc. aortic aneurysm
Resection of coarctation
Closure of VSD
Miscellaneous
Average valve size
BIO
100
81/19
45(5-73)*
45
40
15
2-5*
2-9*
18*
3
4
3
0
2
6
28-2
BS
139
112/27
51(22-72)*
56
63
20
2-8*
2-6*
54*
12
6
15
2
4
15
28-2
Total
239
193/46
48
101
103
35
2-7
2-7
72
15
10
18
2
6
21
28-2
NYHA = New York Heart Association; ci. = cardiac index; CABG = coronary artery
bypass grafting; VSD = ventricular septal defect.
*P < 0005.
Table 2 Mortality
BIO
Early (< 30 days) 1
Late 4
Mean follow-up time 13 and
BIO and BS, respectively.
BS
4
6
20 months
Total
5 (2%)
10(4%)
for patients with
Table 3 Thwinboembolic
complications
Emboli
Valve thrombosis
Hemorrhage
Total
Episodes/100 patient-years
and anticoagulation
BIO
3
3*
2-8
related
BS
8
4
12*
5-3
Results
MORTALITY
Early and late mortality have been similar in
both groups (Table 2). The cause of death was
cardiac, but not valve related, in all patients
[myocardial failure in nine (four early, five late),
sudden unexplained death in six (one early, five
late)]. Autopsies in three of the four late deaths with
BIO and two of the six late deaths with BS were
obtained. The prostheses in all cases examined
were intact and functioning normally.
INCIDENCE OF THROMBOEMBOLISM (TE) AND ANTI-
COAGULANT HEMORRHAGE
All recorded emboli were cerebral; none was
fatal. Emboli in patients with BIO caused minor
transient symptoms only whereas three patients
with BS sustained a hemiplegia with variable
*P = not significant; (n BIO, 99; n BS, 135).
recovery. The total incidence of episodes however
has statistically not been significantly different
between the two groups, although calculated per
100 patient years (Table 3), it has been almost
twice as high in patients with BS.
VALVE FAILURE
Severe regurgitation requiring reoperation oc-
curred in both groups with almost equal frequency
(Table 4). A murmur of mild, hemodynamically in-
significant regurgitation was observed more often in
patients with BIO (P<005); its cause and conse-
quences remain unknown. The average valve size
of patients with such a murmur was 29 and 28-6 in
the BIO and BS groups, respectively. This is
statistically not different from the mean valve size
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Table 4 Prosthetic valve dysfunction and endocarditis
BIO BS
Reoperation because of
endocarditis 1 1
Reoperation in absence of
endocarditis (paravalvular leak) 1 1
Endocarditis, conservatively
treated 1 1
Regurgitant murmur of
unknown cause, no reoperation 9* 3*
*P<005; (n BIO, 99; n BS, 135).
Table 5 Postoperative clinical classification compared to
preoperative class (N YHA)
Preoperative class
II
III
IV
Average postoperative class
A.
BIO
1-3
1-8
1-8
BS *
1-3
1-6
20
used in the entire group of patients. Seven of the
nine patients with a murmur complicating a BIO
had a Carpentier Edwards, one an Angell-Shiley
and one a Hancock prosthesis.
POSTOPERATIVE CLINICAL CLASSIFICATION AND
REDUCTION IN HEART SIZE
The average six months postoperative clinical
improvement has been similar in both groups
(Table 5). Objectively this was documented by a
reduction in heart size assessed by pre- and post-
operative CTR (Table 6). Good quality chest
X-rays were available in 188 patients preopera-
tively and in 155 postoperatively. Patients with
aortic regurgitation (AR) showed a greater reduc-
tion of their postoperative CTR than patients with
aortic stenosis (AS). Little change (< 5% reduction)
was observed in eight of 60 patients with AR (two
BIO, six BS). Nine of 59 patients with AS demon-
strated an increase in postoperative CTR (five BIO,
four BS); of 18 patients with AS and a small pros-
thesis (25 or smaller, six BIO and 12 BS) the heart
size enlarged postoperatively in only three (all BS).
Comment
The purpose of this analysis has been to point out
clinical characteristics of the BIO compared to the
BS. Although the two groups of patients are not
prospectively randomized and are different in some
respects, certain comparisons are still justified.
As expected there are no differences in early and
late mortality. Sudden unexplained death repre-
sents half of the late mortality in both groups. Peri-
operative tachyarrhythmias were a predisposing
factor since all of these patients had to be treated for
arrhythmias early postoperatively; four of the five
patients had aortic regurgitation preoperatively. A
similarly high incidence of sudden late death has
been reported in the series of Copeland!5! and
Davila!6!.
The lower TE complication rate is the major
advantage of the BIO over the BS. Comparing
the two groups in our series with regard to TE
is, however, difficult because they differ in age and
state of the disease. BS patients, who represent the
less favourable group, show a higher incidence of
emboli, although it is statistically not significant.
The fact that the great majority of BIO patients
have not been on long-term anticoagulants and that
emboli in this group presented as minor transi-
ent episodes only, contrary to BS patients, weighs
in favour of this type of valvular substitute. Our
incidence of 2-8 episodes per 100 patient years for
BIO patients is within the range of what is generally
reported!'~IO1. As the follow-up period extends, this
rate is likely to drop for BIO patients!9!. This, how-
ever, is not the case for patients with a BS as has
been reported from our institution in patients
followed over a six year period!' •].
An unexplained complication, though not yet
assessable in its significance, has been the occur-
rence of a regurgitant murmur in the absence of
endocarditis in 10% of patients with BIO (com-
pared to 2% in BS patients). A similar observation
has been made by Pipkin!2!. Whether the origin of
this murmur is valvular or paravalvular cannot be
determined clinically nor by echocardiography.
The valve size per se is not a predictor for the
occurrence of such a murmur. On the other hand
we always have tried to insert a BIO as large as
possible to minimize the postoperative gradients
which have been""described in clinical and experi-
mental studies with this type of valvular
device!12'13!. One might speculate that the intention
to insert a large prosthesis has led to a dispro-
portion between anulus and prosthetic ring
resulting in a paravalvular leak. The bulkier ring of
the Angell-Shiley prosthesis may also provide a
better seal than the Carpentier Edwards ring since
most murmurs appeared in patients with the latter
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Table 6 Postoperative reduction ofCTR *
Prcoperative lesion
Regurgitation
BIO
BS
Stenosis
BIO
BS
Mixed lesion
BIO
BS
Preoperative CTR
(mean)
056
0-57
0-50
0-54
050
0-53
Postoperative CTR
(mean)
050
0-51
0-48
0-50
047
0-50
%Reduction
11
11
4
7
6
6
*CTR = Cardiothoracic ratio.
valve. We now pay particular attention so as not to
insert too large a prosthesis for a given anulus. If
necessary a patch enlargement of the aortic root
into the non-coronary sinus will allow implan-
tation of a prosthesis of appropriate size. Post-
operative results, judged by the NYHA classifi-
cation have been good in both groups without
significant differences. As a more objective para-
meter to follow postoperative recovery we have
compared CTR of pre- and six months, post-
operative chest X-rays. Reduction in CTR has been
independent of valve type. There were altogether
13% of AR patients and 15% of AS patients with
poor reduction or an increase of their postoperative
CTR. This is of prognostic importance; particu-
larly for patients with AR. In an earlier series of
AVR with various mechanical devices RothlinI"]
has statistically documented a worse prognosis for
patients with little or no reduction in heart size
postoperatively (six years follow-up). This has been
the case also for patients with marked preoperative
cardiomegaly (CTR>0'6) and those in preopera-
tive clinical class IV.
At present we continue to use BS and BIO for
AVR, but the latter has become the prosthesis of
first choice because of the lower incidence of
thromboembolism. Uncertain durability, however,
remains its major drawback, but our earlier experi-
ence with patients with fascia lata valves supports
the concept that a reoperation after several years
because of valve fatigue or degeneration is pre-
ferable to the continued risk of thromboembolism
and anticoagulant hemorrhage!14]. We reserve the
BS, therefore, for patients already on anticoagu-
lants for other reasons, those already reoperated, or
patients in an advanced state of disease.
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